Contraceptives: Opportunity Analysis and Forecasts to 2027
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hormonal contraceptives are primarily used to prevent unintended pregnancy; however, some of these contraceptives are also approved or used off-label for other health conditions, particularly menstrual-related disorders. This report focuses on female hormonal contraceptives used for birth control as well as other non-contraceptive benefits distinct from their ability to prevent pregnancy. Female hormonal contraceptives are used in women of reproductive age, which according to the World Health Organization (WHO) refers to all women ages 15–49 years.
GlobalData estimates the 2017 sales for the contraceptives market at approximately $6.34 billion across the 8MM, encompassing the US, the five major European countries (5EU: France, Germany, Italy, Spain, and UK), Japan, and China. By 2027, GlobalData expects the overall market to grow at a moderate compound annual growth rate (CAGR) of 2.7% to reach sales of $8.24 billion over the 10-year period. The Chinese market is anticipated to grow the fastest, recording a CAGR of 6.2%, while the US, 5EU, and Japan will each record CAGRs of 4.8%, -0.5%, and -1.1%, respectively. At the end of 2027, the US will contribute around 63.5% of global sales, while the 5EU, Japan, and China will account for 78.6%, 16.7%, and 4.7% of global sales, respectively.
Key Questions Answered
Combination oral contraceptives (COCs) have dominated the contraceptives market for many years. However, there has been an increased usage of other contraceptive routes of administration, such as hormonal intrauterine devices (IUDs), vaginal rings, and subcutaneous implants. What are the treatment trends during the forecast period? What factors do women take into account when choosing a contraceptive?
There are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the contraceptives market?
How will the entrance of the five late stage pipeline drugs affect the global contraceptive treatment landscape?
Scope
Overview of contraceptives, including patterns of treatment, unmet needs and opportunity, current treatment landscape, pipeline drug analysis, and R&D strategies.
Annualized contraceptives market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the contraceptives market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global contraceptives market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving the global contraceptives market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global contraceptives market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global contraceptives market from 2017-2027.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Allergan
Antares Pharma Bayer
ContraMed
Exeltis Germany
Evofem Biosciences
Fuji Pharma Co.
Merck
Mithra Pharmaceuticals
Pfizer
The Population Council
Sebela Pharma
Therapeutics MD
Viramal Ltd
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.